• Design and development of novel tumour-targeted anti-cancer therapeutic systems

• Design and development of novel therapeutic systems able to reach the brain after systemic administration, with the ultimate aim to facilitate drug delivery to brain tumours and neurogenerative disorders.

09 / 2007: Postgraduate Certificate in Advanced Academic Studies, University of Strathclyde

12 / 2002: PhD (with European Label,with the highest distinction and the congratulations of the jury), University of Poitiers, France

07/1999: Diplôme d’études approfondies (with distinction) (French equivalent to a MRes, which is mandatory for PhD candidates in France), University of Poitiers

12/1997: Doctorate of Pharmacy with a specialization in Industry and Research (with the highest distinction and the congratulations of the jury), University of Poitiers

09/1996: Maîtrise de Sciences biologiques et médicales (with distinction) (French equivalent to a MSc in Medical and Biological Sciences), University of Poitiers

• Tumour regression/disappearance after intravenous administration of a novel tumour-targeted polypropylenimine dendrimer combined with Tumour Necrosis Factor expression plasmid, with complete disappearance of 90% of the tested tumours and regression of the remaining ones. These results are highly important, as there is currently no gene medicine commercially available for the intravenous treatment of cancer.

• Tumour regression/disappearance after intravenous administration of the vitamin E extract tocotrienol entrapped in novel tumour-targeted vesicles, with complete disappearance of 40% of the melanoma tumours (doctoral work of Ms Ju Yen Fu). It is the first time that a tocotrienol formulation led to tumour suppression.

• Increase of gene expression in tumours by surface modification of polyethylenimine and polypropylenimine dendrimers with the amino acids arginine, lysine and leucine (doctoral work of Ms Hibah Aldawsari).

• Tumour regression using synthetic vectors to express a novel p53-derived apoptotic peptide able to de-repress p73 (post-doctoral work, PI: Prof. K. Ryan, Dr A. Schätzlein).

• Tumour regression after intravenous administration of a pharmacologically active dendrimer combined with Tumour Necrosis Factor expression plasmid driven by a tumour-specific promoter (post-doctoral work, PI: Dr A. Schätzlein, Prof. I. Uchegbu).

• Discovery of the intrinsic anti-cancer activity of some polymers and dendrimers (A. Schätzlein, I.F. Uchegbu, C. Dufès, Bioactive polymers, WO/2006/040579).

• Brain delivery of Vasoactive Intestinal Peptide (VIP) after nasal administration (doctoral work, PI: Prof. J.-M. Muller, Prof. J.-C. Olivier).

• Brain delivery of Vasoactive Intestinal Peptide (VIP) after intravenous administration of targeted niosomes (doctoral work, PI: Prof. J.-M. Muller, Prof. I. Uchegbu, Dr A. Schätzlein, Prof. J.-C. Olivier).